Omicron challenges drug efficacy; Pfizer's Paxlovid shows promise

When the Omicron variant emerged in late November, it arrived with a question that pharmaceutical companies and infectious disease specialists could not yet answer: would the drugs already in use against COVID-19 still work? The new strain's defining characteristic was a cluster of mutations concentrated on the spike protein—the very part of the virus that most existing treatments had been designed to attack. Within days, the race was on to test whether these medications would retain their power against this new version of the disease.

The World Health Organization moved quickly to offer partial reassurance. On November 28, it declared that certain drugs used for severe COVID cases—corticosteroids and blockers of the interleukin-6 receptor—would continue to work against Omicron. These medications do not target the virus itself but rather modulate how the human immune system responds to infection, dampening the dangerous inflammation that can lead to respiratory failure. Because they work on the body's reaction rather than on viral structures, the mutations in Omicron posed no threat to their effectiveness. But for other treatments, the picture remained murky, and manufacturers scrambled to gather data.

Pfizer moved first with concrete news. On December 14, the company announced that laboratory studies confirmed its antiviral pill Paxlovid retained full efficacy against Omicron. The drug works by targeting the protease enzyme—the molecular machinery the virus uses to break down its own proteins into functional pieces. Because this enzyme had not undergone significant mutation in the new variant, Paxlovid's mechanism remained intact. Merck made a similar claim about its pill Molnupiravir, arguing that it too attacked viral components that had escaped mutation. Both drugs were already in clinical trials in Brazil and represented a different strategic approach than the monoclonal antibody treatments that had dominated the early pandemic response.

The monoclonal antibody drugs told a different story. These medications work by flooding the bloodstream with laboratory-manufactured antibodies before the virus can establish itself—a strategy borrowed from older treatments like rabies and tetanus serums. Four such drugs had been authorized for use in Brazil: sotrovimabe, made by GSK; the Regen-CoV cocktail from Regeneron and Roche; a combination of banlanivimabe and etesevimab from Eli Lilly; and regdanvimabe. All of them targeted the spike protein, the very structure that had mutated most heavily in Omicron. On December 7, GSK claimed sotrovimabe would still work, though the company acknowledged its data required peer review. The other manufacturers were less confident. Regeneron and Roche suggested their cocktail might lose potency. Eli Lilly said it was still evaluating the question. The manufacturer of regdanvimabe had not yet commented publicly.

João Prats, an infectious disease specialist at Beneficiência Portuguesa in São Paulo, explained the underlying vulnerability. "Because these are medications that attack the spike protein—the one showing the most mutation—the likelihood of reduced efficacy increases," he said. The spike protein had become a moving target, and the pressure driving its evolution came partly from the vaccines themselves. As more of the global population became immunized, the virus faced selective pressure to modify the very structure that vaccines trained the immune system to recognize. Celso Granato, a virologist and director of the Fleury Group, noted that this dynamic could produce future variants with mutations in other viral regions, potentially creating new challenges for treatments targeting different parts of the pathogen.

Remdesivir, an intravenous antiviral used for hospitalized patients requiring oxygen support, occupied middle ground. Its manufacturer expressed hope it would remain effective but committed to conducting laboratory tests to verify this assumption. The immune-modulating drugs tocilizumab and sarilumab, used for severe cases since July according to WHO guidance, faced no threat from Omicron because they too worked on the immune response rather than the virus itself. Baricitinib, the most recently approved drug in Brazil, operated through the same immune-modulation pathway and would similarly be unaffected.

By mid-December, the picture had become clearer but not entirely reassuring. The drugs most likely to retain full power were those that either attacked viral machinery that had not mutated or that worked on the human immune system rather than the virus itself. The monoclonal antibodies—a class of drug that had seemed so promising in the pandemic's earlier phases—now faced an uncertain future against this new strain. Manufacturers were conducting studies, but the results would take time. In the meantime, clinicians would need to make treatment decisions based on incomplete information, and patients would face a landscape of medications with varying degrees of proven effectiveness against the variant that now dominated global transmission.